Skip to main content

Evidence map for any claim

Claimscape

Type a claim and see where the literature stands on it. Every relevant abstract on PubMed is read, sorted by study design and plotted by year, so you can see which kinds of evidence agree and how that changed over time.

  • Each dot is a paper, colored by what its abstract reports
  • Rows are study designs, each with a verdict and a 95% interval
  • Every dot opens the sentence its verdict rests on
Papers to read
Examples

Example map

The strongest evidence here, 4 meta-analyses and systematic reviews, is split.

Randomized trials mostly go against it (24% of 37 for). Most papers with a verdict are observational studies (47), which are split.

Claim: “Hormone replacement therapy reduces the risk of coronary heart disease in postmenopausal women”

PubMed matches
593
for the search, before any reading
Read
200
top 200 by relevance
On topic
133
study the claim's question
On the map
129
sorted by study type
With a verdict
90
counted in the summaries

129 papers · stored example

For the claimMixedAgainst the claimUnclearNo result on the claimHollow: indirect evidenceConfidence

2025·Cochrane Database Syst Rev·PMID 41307293·doi

Long-term hormone therapy for perimenopausal and postmenopausal women.

Against the claim

For the claim0%
Mixed0%
Against the claim100%
No result on the claim0%

Both readings agree. Averaged over two differently worded questions.

Study type
Meta-analyses & systematic reviewsPubMed type: Systematic Review
Evidence
Tests the claim directly93% direct
On topic
97%

Abstract

Based on this study, combined continuous hormone therapy probably makes little to no difference to the risk of a coronary event (RR 1.17, 95% CI 0.95 to 1.44; moderate-certainty evidence).

The full abstract couldn't be loaded. Read it on PubMed.

This is what the abstract reports, read by an AI model. Check the paper before relying on it. Have the PDF? Rigor Scan checks how completely it reports its methods.

Reading the map

  • Rows are study designs, strongest first. Reviews and commentary are shown but never counted.
  • Each dot is one paper, placed at its publication date. Color is what its abstract reports about the claim; stronger color means a more confident reading.
  • Hollow dots test the claim indirectly: another population, species or model, or a stand-in outcome. Turn on “Direct evidence only” to drop them.
  • A row's verdict needs at least 3 papers with a verdict. The dot and bar under it show the share for, with its 95% interval against the 50% line.
  • This maps what abstracts claim, not effect sizes. It is not a meta-analysis, and published literature leans toward positive findings.

Search used: Hormone replacement therapy coronary heart disease postmenopausal women, research papers only. Open it on PubMed

Take it further with K-Dense Web

This map is built from 129 abstracts. K-Dense Web can read the full papers, extract effect sizes and run the meta-analysis. Pick what to send.

The brief lists the claim, the search, each design's verdicts and the PubMed IDs on the map. K-Dense Web fetches the papers itself.

Every paper on the map

129 of 129 shown. Select a row to read its abstract.

PaperEvidence
2025Cochrane Database Syst RevMeta-analyses & systematic reviewsPubMed typeAgainst the claim100%Direct
2025JAMA Intern MedRandomized trialsPubMed typeAgainst the claim76%Direct
2024ClimactericObservational studiesRead from abstractFor the claim81%Direct
2020Circ Genom Precis MedObservational studiesPubMed typeMixed80%Direct
2020Cancer Prev Res (Phila)Reviews & commentaryRead from abstractAgainst the claim100%Direct
2020MenopauseRandomized trialsPubMed typeMixed62%Direct
2019Prev Med RepObservational studiesRead from abstractAgainst the claim72%Indirect
2019Hum Reprod UpdateMeta-analyses & systematic reviewsPubMed typeMixed95%Direct
2019MenopauseObservational studiesRead from abstractAgainst the claim100%Direct
2018MenopauseRandomized trialsPubMed typeAgainst the claim95%Indirect
2017J Am Heart AssocRandomized trialsPubMed typeUnclear48%Direct
2017ClimactericReviews & commentaryRead from abstractUnclear37%Indirect
2017Cochrane Database Syst RevMeta-analyses & systematic reviewsPubMed typeAgainst the claim84%Direct
2016ClimactericReviews & commentaryRead from abstractUnclear58%Indirect
2016N Engl J MedRandomized trialsPubMed typeMixed96%Indirect
2015J Clin Endocrinol MetabObservational studiesRead from abstractUnclear46%Indirect
2015MenopauseObservational studiesRead from abstractFor the claim99%Direct
2015Cochrane Database Syst RevMeta-analyses & systematic reviewsPubMed typeMixed84%Direct
2014Obstet GynecolObservational studiesRead from abstractFor the claim93%Direct
2014Ann Intern MedRandomized trialsPubMed typeAgainst the claim94%Indirect
2013JAMARandomized trialsPubMed typeAgainst the claim74%Direct
2012MenopauseObservational studiesRead from abstractAgainst the claim67%Direct
2011Arterioscler Thromb Vasc BiolObservational studiesRead from abstractAgainst the claim100%Direct
2011MenopauseRandomized trialsPubMed typeUnclear51%Indirect
2010Am Heart JRandomized trialsPubMed typeAgainst the claim98%Indirect
2010ClimactericRandomized trialsRead from abstractFor the claim69%Indirect
2010Am Heart JRandomized trialsPubMed typeAgainst the claim89%Indirect
2010Ann Intern MedRandomized trialsPubMed typeAgainst the claim71%Direct
2009Womens Health (Lond)Reviews & commentaryRead from abstractMixed100%Direct
2009Am J EpidemiolRandomized trialsPubMed typeAgainst the claim100%Direct
2009MenopauseRandomized trialsPubMed typeAgainst the claim95%Indirect
2009Menopause IntReviews & commentaryRead from abstractUnclear54%Direct
2009LupusObservational studiesRead from abstractAgainst the claim97%Indirect
2008Gynecol EndocrinolObservational studiesRead from abstractAgainst the claim98%Direct
2008Arch Intern MedRandomized trialsPubMed typeAgainst the claim100%Direct
2008EpidemiologyObservational studiesRead from abstractAgainst the claim69%Direct
2008MenopauseObservational studiesRead from abstractAgainst the claim100%Direct
2007Am J EpidemiolReviews & commentaryRead from abstractAgainst the claim91%Indirect
2007Curr Opin CardiolReviews & commentaryRead from abstractAgainst the claim100%Direct
2007N Engl J MedRandomized trialsPubMed typeFor the claim80%Indirect
2007Hum ReprodObservational studiesRead from abstractMixed62%Direct
2007PLoS MedObservational studiesRead from abstractMixed73%Direct
2007JAMARandomized trialsPubMed typeMixed81%Direct
2006MaturitasRandomized trialsPubMed typeAgainst the claim100%Direct
2006MenopauseReviews & commentaryRead from abstractMixed71%Indirect
2006Arch Intern MedRandomized trialsPubMed typeUnclear59%Direct
2005MenopauseObservational studiesRead from abstractFor the claim96%Indirect
2005Thromb HaemostObservational studiesRead from abstractAgainst the claim87%Indirect
2005J Womens Health (Larchmt)Observational studiesRead from abstractMixed92%Indirect
2005Int J CardiolRandomized trialsRead from abstractAgainst the claim97%Indirect
2005Korean J Intern MedRandomized trialsRead from abstractMixed84%Indirect
2005HypertensionRandomized trialsPubMed typeAgainst the claim66%Indirect
2004J Womens Health (Larchmt)Observational studiesRead from abstractAgainst the claim100%Indirect
2004J Clin Endocrinol MetabRandomized trialsPubMed typeAgainst the claim99%Indirect
2004Am Heart JRandomized trialsPubMed typeUnclear57%Direct
2004J Manag Care PharmReviews & commentaryRead from abstractAgainst the claim100%Direct
2004Gynecol EndocrinolRandomized trialsPubMed typeFor the claim73%Indirect
2004Prescrire IntReviews & commentaryRead from abstractAgainst the claim100%Direct
2004JAMARandomized trialsPubMed typeAgainst the claim100%Direct
2003J Clin Endocrinol MetabObservational studiesRead from abstractUnclear66%Indirect
2003N Engl J MedRandomized trialsPubMed typeAgainst the claim99%Indirect
2003Minerva GinecolRandomized trialsPubMed typeAgainst the claim99%Indirect
2003Am Heart JObservational studiesRead from abstractAgainst the claim99%Indirect
2003Prescrire IntReviews & commentaryRead from abstractAgainst the claim100%Direct
2003Br J Gen PractObservational studiesRead from abstractAgainst the claim100%Direct
2003Int J CardiolObservational studiesRead from abstractFor the claim89%Indirect
2002LancetRandomized trialsPubMed typeAgainst the claim99%Indirect
2002Control Clin TrialsRandomized trialsRead from abstractNo result on the claim100%Indirect
2002J Womens Health Gend Based MedObservational studiesRead from abstractAgainst the claim93%Indirect
2002GeriatricsReviews & commentaryRead from abstractAgainst the claim100%Direct
2002JAMARandomized trialsPubMed typeAgainst the claim100%Direct
2002CirculationRandomized trialsPubMed typeAgainst the claim96%Direct
2002CirculationRandomized trialsRead from abstractAgainst the claim99%Indirect
2002J Am Coll CardiolRandomized trialsPubMed typeAgainst the claim97%Indirect
2001Arterioscler Thromb Vasc BiolObservational studiesRead from abstractMixed84%Indirect
2001Blood Coagul FibrinolysisCase reports & seriesRead from abstractUnclear47%Indirect
2001Ann Intern MedRandomized trialsPubMed typeUnclear58%Indirect
2001Ann Intern MedRandomized trialsPubMed typeUnclear44%Indirect
2001MaturitasObservational studiesRead from abstractFor the claim98%Indirect
2001Arterioscler Thromb Vasc BiolRandomized trialsPubMed typeAgainst the claim99%Indirect
2001JAMAObservational studiesRead from abstractAgainst the claim83%Direct
2000Ann Intern MedObservational studiesRead from abstractFor the claim85%Direct
2000EpidemiologyObservational studiesRead from abstractAgainst the claim64%Direct
2000Cardiol RevReviews & commentaryRead from abstractMixed100%Direct
2000Control Clin TrialsRandomized trialsPubMed typeNo result on the claim100%Indirect
2000JAMARandomized trialsPubMed typeMixed62%Indirect
2000J Gerontol A Biol Sci Med SciObservational studiesRead from abstractFor the claim96%Indirect
1999Arterioscler Thromb Vasc BiolRandomized trialsPubMed typeMixed69%Indirect
1999MetabolismObservational studiesRead from abstractFor the claim96%Indirect
1999Thromb HaemostRandomized trialsPubMed typeFor the claim75%Indirect
1999Arterioscler Thromb Vasc BiolObservational studiesRead from abstractMixed85%Indirect
1999MetabolismObservational studiesRead from abstractFor the claim77%Indirect
1998Arterioscler Thromb Vasc BiolRandomized trialsPubMed typeFor the claim89%Indirect
1998J Clin PharmacolObservational studiesRead from abstractFor the claim83%Indirect
1998Diabetes CareObservational studiesRead from abstractFor the claim79%Indirect
1998JAMARandomized trialsPubMed typeAgainst the claim99%Direct
1998Control Clin TrialsRandomized trialsPubMed typeNo result on the claim100%Indirect
1998Am J CardiolObservational studiesRead from abstractFor the claim86%Indirect
1998J Am Coll CardiolObservational studiesRead from abstractFor the claim89%Indirect
1998CirculationRandomized trialsPubMed typeAgainst the claim93%Indirect
1998Br J HaematolObservational studiesRead from abstractFor the claim94%Indirect
1998Proc Soc Exp Biol MedReviews & commentaryRead from abstractUnclear66%Indirect
1998Control Clin TrialsRandomized trialsPubMed typeNo result on the claim100%Direct
1998MaturitasRandomized trialsPubMed typeUnclear35%Indirect
1997Am Heart JObservational studiesRead from abstractFor the claim85%Direct
1997J Am Coll CardiolObservational studiesRead from abstractFor the claim89%Indirect
1997N Engl J MedObservational studiesRead from abstractUnclear49%Indirect
1997Obstet GynecolObservational studiesRead from abstractFor the claim99%Indirect
1997Am J CardiolObservational studiesRead from abstractFor the claim87%Indirect
1997J Am Coll CardiolObservational studiesRead from abstractFor the claim97%Indirect
1996Am J MedReviews & commentaryRead from abstractFor the claim99%Indirect
1996Am J Geriatr CardiolReviews & commentaryRead from abstractNo result on the claim95%Indirect
1996N Engl J MedObservational studiesRead from abstractFor the claim99%Direct
1996J Thromb ThrombolysisReviews & commentaryRead from abstractFor the claim87%Indirect
1996Obstet GynecolReviews & commentaryRead from abstractFor the claim99%Direct
1995Am J Public HealthObservational studiesRead from abstractUnclear39%Direct
1995LancetRandomized trialsRead from abstractFor the claim90%Indirect
1995J Am Med Womens Assoc (1972)Reviews & commentaryRead from abstractNo result on the claim100%Indirect
1994J Am Coll CardiolAnimal studiesRead from abstractMixed62%Indirect
1994CirculationObservational studiesRead from abstractFor the claim89%Indirect
1993Cardiovasc ResCell & molecular studiesRead from abstractFor the claim92%Indirect
1993Thromb HaemostObservational studiesRead from abstractFor the claim79%Indirect
1993Br J HaematolObservational studiesRead from abstractUnclear44%Indirect
1992Womens Health IssuesReviews & commentaryRead from abstractFor the claim79%Indirect
1991N Engl J MedObservational studiesRead from abstractFor the claim100%Direct
1990Arch Intern MedObservational studiesRead from abstractUnclear59%Indirect
1990Obstet GynecolObservational studiesRead from abstractFor the claim95%Indirect
1990GeriatricsReviews & commentaryRead from abstractFor the claim96%Indirect
1989N Engl J MedObservational studiesRead from abstractFor the claim71%Indirect
  1. 1

    Search PubMed

    Your claim becomes a PubMed search you can edit. The top 200 papers by relevance are fetched, with retracted papers and notices removed.

  2. 2

    Read every abstract

    An AI model answers the same six questions of each abstract: is it on topic, which way it points (asked two ways), whether it tests the claim directly, what kind of study it is, and which sentence holds the finding.

  3. 3

    Sort by design

    PubMed's own publication types decide the study design where they're clear. Otherwise the model's reading of the abstract does, and the page says which.

  4. 4

    Summarize with intervals

    Each design gets a share for with a 95% interval. The headline is built from fixed rules over those rows, starting with the strongest design.

What it is, and isn't

  • A map of what published abstracts report about a claim, and how that differs by study design and over time.
  • Not a meta-analysis: papers aren't weighted by size or quality, and effect sizes aren't pooled.
  • K-Dense doesn't store or log your claims. The claim is sent with the public abstracts to be read, and the map lives in your tab.

Method v0.1 · September 23, 2026

How the map is made

Everything that decides a map is published here: the search, every question exactly as it is asked, every threshold and every rule. The launch post walks through worked examples and how to use a map.

The questions asked of every abstract

Each abstract is read on its own, with the claim beside it: { claim, paper: { title, abstract } }. The abstract is split into sentences, each prefixed with an id (S01|). The model returns a probability for every option; it doesn't write text.

1. On topic (yes or no)

“Does the paper investigate the relationship described in the claim?”

  • yesThe paper studies or reviews the same kind of exposure or intervention and the same kind of outcome as the claim, in any population, species or model
  • noThe paper is about a different question, or mentions the claim's topic only in passing

2 and 3. Verdict, asked two ways (one option)

“What do the paper's own results say about the claim?” and “Taken as a whole, which way does the paper's evidence point on the claim?”

  • supportsThe paper's results or conclusions agree with the claim For example: An effect in the direction the claim states; No effect, when the claim is that there is none.
  • contradictsThe paper's results or conclusions disagree with the claim For example: No effect or no association where the claim asserts one; An effect in the opposite direction to the claim; Harm where the claim asserts benefit.
  • mixedSome results agree with the claim and others disagree, for example across outcomes, doses, subgroups or time
  • no_resultThe paper reports no result that bears on the claim For example: A study protocol or method; A review that describes the topic without reaching a conclusion.

4. Direct evidence (yes or no)

“Does the paper test the claim directly?”

  • yesThe paper studies the same population, exposure or intervention, and outcome that the claim names
  • noThe paper uses a different population, species or laboratory model, or a stand-in exposure or outcome

5. Study type (one option)

“What kind of study is this paper?”

  • meta_analysisSystematic review or meta-analysis that pools results from several studies
  • rctRandomized controlled trial in people
  • observationalStudy of people without random assignment: cohort, case-control, cross-sectional, registry, database or retrospective analysis, or a non-randomized trial
  • case_reportCase report or case series describing individual patients
  • animalExperiments in live animals
  • in_vitroLaboratory experiments on cells, tissues or molecules without live animals
  • reviewNarrative review, commentary, editorial, guideline or opinion without its own pooled analysis
  • otherModeling, simulation, methods, protocol or anything else

6. Finding (one of the abstract's own sentences)

“Which sentence of the abstract reports this paper's own result that bears most directly on the claim?”

The options are the abstract's sentence ids, so the highlighted finding is always text the paper contains.

Search

  • The claim becomes PubMed search terms by dropping direction words (“reduces”, “increases”) and filler, so papers aren't missed for using a different verb. You can edit the search.
  • Every search adds hasabstract AND english[la]. Unless you ask for narrative reviews and commentary, it also adds NOT ((review[pt] NOT systematic[sb]) OR editorial[pt] OR comment[pt] OR letter[pt] OR news[pt]), which keeps systematic reviews.
  • The top 100, 200, 300 papers by PubMed Best Match are read, whichever you choose.
  • If PubMed doesn't recognize a search term it quietly searches without it. Claimscape stops instead and names the term, so a typo can't change the question.
  • Removed before reading: Retracted Publication, Retraction of Publication, Published Erratum, Expression of Concern.
  • Changing only the claim re-reads the same papers, so you can see how wording moves the map.

Verdicts and summaries

  • A paper is on the map when its on-topic answer is at least 50%, and counts as direct evidence at 50% or more.
  • Its verdict counts when both readings pick the same option and their average is at least 60%. Otherwise it is unclear.
  • Reviews and commentary are shown but never counted.
share for = (for + mixed / 2) / (for + mixed + against)
interval  = Wilson score, 95%
Too few to say
Fewer than 3 papers with a verdict.
Mostly for
The lower end of the 95% interval is above 50% and the share for is at least 75%.
Leans for
The lower end of the 95% interval is above 50%.
Mostly against
The upper end of the 95% interval is below 50% and the share for is at most 25%.
Leans against
The upper end of the 95% interval is below 50%.
Split
The 95% interval includes 50%.

The headline names the verdict of the strongest design that has one, then the first other design that points the opposite way.

Study type

PubMed publication types, assigned by NLM indexers, decide the row when they are clear. Rules are checked in order and the first match wins. An abstract indexed only as “Review” moves to meta-analyses when the model reads it as one at 80% or more.

Meta-analyses & systematic reviews
Meta-Analysis, Systematic Review
Animal studies
Randomized Controlled Trial, Veterinary, Clinical Trial, Veterinary, Observational Study, Veterinary
Randomized trials
Randomized Controlled Trial
Case reports & series
Case Reports
Observational studies
Observational Study
Reviews & commentary
Review, Editorial, Comment, Letter, News, Guideline, Practice Guideline, Consensus Development Conference, Consensus Development Conference, NIH

Otherwise the model's answer to question 5 decides:

meta_analysis
Meta-analyses & systematic reviews
rct
Randomized trials
observational
Observational studies
case_report
Case reports & series
animal
Animal studies
in_vitro
Cell & molecular studies
review
Reviews & commentary
other
Left off the map

Rows, strongest first: Meta-analyses & systematic reviews, Randomized trials, Observational studies, Case reports & series, Animal studies, Cell & molecular studies, Reviews & commentary.

Limits

  • Abstracts only. An abstract can overstate or understate what the paper found, and results reported only in the full text are missed.
  • Every paper counts once, whatever its size or quality. A small pilot study and a large trial look the same.
  • Published literature leans toward positive findings, so null results are under-represented before anything is read.
  • The search shapes the map. PubMed's relevance ranking decides which papers are read; check the search and open it on PubMed.
  • The model reads claims literally, including scope words like “in older adults”. Plain, positive claims work best; negations are read less reliably.
  • The AI can misread. Every dot opens its abstract with the sentence it rests on highlighted, so you can check it.
  • English-language papers with abstracts only.
  • The method is versioned. Compare maps only within the same version.

Abstracts and publication types come from PubMed through the NCBI E-utilities, courtesy of the U.S. National Library of Medicine. Claimscape isn't affiliated with or endorsed by NLM.

Also free from K-Dense: Rigor Scan, a reporting check for a single paper.

Examples were built on September 24, 2026 and reflect PubMed on that date. A live map of the same claim can differ as new papers are indexed.